Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Previous studies have suggested that statins can be repurposed for cancer treatment. However, the therapeutic efficacy of statins in chronic myeloid leukemia (CML) has not yet been demonstrated. In this study, we retrospectively evaluated the outcomes of 408 CML patients who underwent imatinib thera...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hyeok-Jae Jang, Young-Min Woo, Kazuhito Naka, Jong-Ho Park, Ho-Jae Han, Hee-Jin Kim, Sun-Hee Kim, Jae-Sook Ahn, Taehyung Kim, Shinya Kimura, Sarah Zarabi, Jeffrey H. Lipton, Mark D. Minden, Chul-Won Jung, Hyeoung-Joon Kim, Jong-Won Kim, Dennis Dong Hwan Kim
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
CML
drug resistance
statin
tyrosine kinase inhibitor
combination therapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/8322a5e3f83e40388263140905c6e5f5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/8322a5e3f83e40388263140905c6e5f5

Ejemplares similares